mTORC2 inhibitor

DRUG CLASS:

mTORC2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
RICTOR amplification	Gastric Cancer	RICTOR amplification	Gastric Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
RICTOR amplification	Small Cell Lung Cancer	RICTOR amplification	Small Cell Lung Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
FGF19 amplification + ER positive	HER2 Negative Breast Cancer	FGF19 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
EGFR mutation + ER positive	HER2 Negative Breast Cancer	EGFR mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF3 amplification + ER positive	HER2 Negative Breast Cancer	FGF3 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF4 amplification + ER positive	HER2 Negative Breast Cancer	FGF4 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
PIK3CA E542Q	HER2 Positive Breast Cancer	PIK3CA E542Q	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA N345K	HER2 Positive Breast Cancer	PIK3CA N345K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E453K	HER2 Positive Breast Cancer	PIK3CA E453K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA H1047R	HER2 Positive Breast Cancer	PIK3CA H1047R	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E542K	HER2 Positive Breast Cancer	PIK3CA E542K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA H1047L	HER2 Positive Breast Cancer	PIK3CA H1047L	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
EWSR1-POU5F1 fusion	Renal Cell Carcinoma	EWSR1-POU5F1 fusion	Renal Cell Carcinoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
PTEN deletion	Renal Cell Carcinoma	PTEN deletion	Renal Cell Carcinoma	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3	talazoparib + PF-05212384 Sensitive: C3 – Early Trials talazoparib + PF-05212384 Sensitive : C3

mTORC2 inhibitor

mTORC2 inhibitor

Associations(76)

Associations
(76)